Prevention of infection transmission during stem cell transplantation

Bláha, M.; Měřička, Pavel; Stepanova,; Splino, M; Malý, J; Jebavý, Ladislav; P, Žák; Cermanová, Melánie; Filip, Stanislav; Błażek, M.; Reháček,

doi:10.1007/bf02931627

Cited by 5 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the window period from the donor testing to the actual cell procurement ensures safety as diseases tested negative initially may become detectable during this window period. Therefore, a minimum of two weeks is advisable for stem cell donors [37,96,98,99,107,112]. Donors are routinely tested for hepatitis A, B, and C viruses, HIV, EBV, CMV, Toxoplasma, and Treponema infections, minimizing the risk of these transmissions [37,78,80,99,102].…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

“…Organ and bone marrow transplantation is a particular area of interest, as these patients are heavily immunocompromised, immunosuppressed, and at a high risk of typical or atypical, unusual infections [ 17 , 97 , 98 ]. Furthermore, an additional risk may appear in the case of bone marrow transplantation, with donor-derived or contaminated pathogen transmission originating from or during the stem cell harvesting or preparing process [ 99 , 100 , 101 , 102 ].…”

Section: Areas Of Particular Interestmentioning

confidence: 99%

See 1 more Smart Citation

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

et al. 2023

View full text Add to dashboard Cite

Transfusion medicine is traditionally a strong/fundamental part of clinical practice, saving hundreds of millions of lives. However, blood-borne or transmitted infections are a well-known and feared possibility, a risk we relentlessly mitigate. Pathogens are continuously and rather quickly changing, so during the last decade, many, sometimes exotic, new pathogens and diseases were recorded and analyzed, and some of them were proved to be transmitted with transfusions. Blood or blood component transfusions are carried out after cautious preparative screening and inactivation maneuvers, but in some instances, newly recognized agents might escape from standard screening and inactivation procedures. Here, we try to focus on some of these proven or potentially pathogenic transfusion-transmitted agents, especially in immunocompromised patients or bone marrow transplantation settings. These pathogens are sometimes new challenges for preparative procedures, and there is a need for more recent, occasionally advanced, screening and inactivation methods to recognize and eliminate the threat a new or well-known pathogen can pose. Pathogen transmission is probably even more critical in hemophiliacs or bone marrow transplant recipients, who receive plasma-derived factor preparations or blood component transfusions regularly and in large quantities, sometimes in severely immunosuppressed conditions. Moreover, it may not be emphasized enough that transfusions and plasma-derived product administrations are essential to medical care. Therefore, blood-borne transmission needs continued alertness and efforts to attain optimal benefits with minimized hazards.

show abstract

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Section: Areas Of Particular Interestmentioning

confidence: 99%

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In vitro culture can modify cell characteristics. There is always a risk of viral, bacterial, or primal infections [127, 128]. Thus the requirement to develop standard procedures within highly regulated GMP laboratories.…”

Section: Limitations and Caution In Clinical Use Of Mscsmentioning

confidence: 99%

The Necessity of a Systematic Approach for the Use of MSCs in the Clinical Setting

Raynaud

Rafii

2013

Stem Cells International

View full text Add to dashboard Cite

Cell therapy has emerged as a potential therapeutic strategy in regenerative disease. Among different cell types, mesenchymal stem/stromal cells have been wildly studied in vitro, in vivo in animal models and even used in clinical trials. However, while clinical applications continue to increase markedly, the understanding of their physiological properties and interactions raises many questions and drives the necessity of more caution and supervised strategy in their use.

show abstract

“…(4) The issues of stem cell origin, manipulation, transformation, and regulation have not been well addressed. For example, the ethical controversy of embryonic stem cells, limitations in the differentiation potential of adult stem cells, altered properties of stem cells following in vitro culture [ 28 ], the risk of infection transmission during stem cell transplantation [ 29 ], and variations in the quality of stem cell preparations from different suppliers [ 30 ]. Additionally, there are regulatory controversies surrounding stem cell therapy in different countries.…”

Section: Introductionmentioning

confidence: 99%

A systematic review, umbrella review, and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet?

et al. 2023

View full text Add to dashboard Cite

Background The success of stem cell therapy for knee osteoarthritis (KOA) in preclinical animal models has accelerated the pace of clinical translation. However, it remains uncertain whether the current scientific evidence supports the clinical application of stem cells in treating KOA. A comprehensive evaluation of the safety and efficacy of stem cell therapies and scientific evidence quality is necessary. Methods Using “stem cells” and “knee osteoarthritis” as the search terms, several databases, including PubMed, Web of Science, Cochrane, Embase, and Clinicaltrials.gov, were searched on August 25, 2022, and updated on February 27, 2023. Clinical studies that reported adverse reactions (ARs) of stem cell therapy in KOA patients were included without limiting the type of studies. Quantitative systematic reviews of stem cell therapy for KOA that conducted meta-analysis were included. Two researchers conducted literature screening and data extraction independently, and the evidence quality was evaluated according to the Institute of Health Economics and AMSTAR 2 criteria. Results Fifty clinical studies and 13 systematic reviews/meta-analyses (SRs/MAs) were included. Nineteen ARs were reported in 50 studies, including five knee-related ARs, seven common ARs, and seven other ARs. Some studies reported over 10% prevalence of knee pain (24.5%; 95% CI [14.7%, 35.7%]), knee effusion (12.5%; 95% CI [4.8%, 22.5%]), and knee swelling (11.9%; 95% CI [3.5%, 23.5%]). Additionally, two studies have reported cases of prostate cancer and breast tumors, respectively. However, these two studies suggest that stem cell therapy does not bring significant ARs to patients. SRs/MAs results revealed that stem cell therapy relieved pain in patients over time but did not improve knee function. However, current clinical studies have limited evidence regarding study objectives, test designs, and patient populations. Similarly, SRs/MAs have inadequate evidence regarding study design, risk of bias assessment, outcome description, comprehensive discussion, and potential conflicts of interest. Conclusions The inefficacy of stem cells, the risk of potential complications, and the limited quality of evidence from current studies precluded any recommendation for using stem cell products in patients with KOA. Clinical translation of stem cell therapies remains baseless and should be cautiously approached until more robust evidence is available. PROSPERO registration number: CRD42022355875.

show abstract

Prevention of infection transmission during stem cell transplantation

Cited by 5 publications

References 11 publications

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

The Necessity of a Systematic Approach for the Use of MSCs in the Clinical Setting

A systematic review, umbrella review, and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet?

Contact Info

Product

Resources

About